Increasing the CPF MediSave Lifetime Withdrawal Limit for IVF and Other Assisted Conception Procedures in Singapore - A Policy White Paper

Singapore should raise the CPF MediSave lifetime withdrawal limit for IVF and other Assisted Conception Procedures to adjust for inflation. However, stringent and robust safeguards are necessary to prevent private IVF clinics from hard-selling dubious IVF add-on procedures with doubtful efficacy.

Alexis Heng Boon Chin

Aug 06, 2026

Raise Singapore's MediSave Lifetime Withdrawal Limit for IVF with Robust Safeguards

Singapore's CPF MediSave lifetime withdrawal limit for IVF—has remained stubbornly fixed at S$15,000 since 2004. This outdated cap, conceived two decades ago, has been silently eroded by inflation, leaving couples to bear an increasingly heavy financial burden. It is time for a reset to S$25,000.

Alexis Heng Boon Chin

Aug 02, 2026

Female Hypergamy and Assortative Mating in Singapore - Addressing Graduate Women’s Mismatched Marriage Expectations is Crucial for Tackling the Nation’s Fertility and Demographic Crisis

Due to women graduating from universities at significantly higher rates than men in Singapore, this has led to a mating gap or marriage squeeze, as highly educated, high-earning women find themselves competing for a dwindling number of men who meet their hypergamous criteria.

Alexis Heng Boon Chin

Jul 30, 2026

PGT-A in Singapore - Down Syndrome Anxiety and Fear in Singapore Among Older Women Can Be Exploited by the IVF Industry to Hard Sell the Controversial PGT-A Technique - A Policy White Paper

The IVF industry exploits Down syndrome anxiety and fear among older women to market PGT-A. Clinical evidence shows no improvement in IVF success rates and exposes misdiagnosis risks. More transparency and stringent regulations are needed to curtail misleading and unethical marketing practices.

Alexis Heng Boon Chin

Jul 19, 2026

Singapore Government Co-funding of Private IVF Treatment: A Competitive Public Tender Procurement Model

This white paper proposes a competitive public tender procurement model for Singapore government co-funding of private IVF treatment, analogous to the established Government Electronic Business (GeBIZ) framework, under which private IVF clinics would submit price-capped bids for basic IVF cycles.

Alexis Heng Boon Chin

Jul 03, 2026

Singapore should not Invest in Research and Development (R&D) of In Vitro Gametogenesis (IVG) Technology for Human Clinical Assisted Reproduction

Singapore’s highly restrictive laws governing assisted reproduction—specifically the ban on surrogacy, the exclusion of same-sex couples from accessing fertility treatments, and strict limits on the number of donor offspring—will severely stifle any return on investment in IVG technology.

Alexis Heng Boon Chin

May 28, 2026

Policy Actions on In Vitro Fertilization (IVF) and Assisted Reproductive Technologies (ARTs) to Address Singapore's Fertility and Demographic Challenges

As the Singapore government deliberates policy actions on IVF and other ARTs to address the nation's low birthrate, it must carefully consider caveats and potential pitfalls to ensure effective and ethically sound outcomes.

Alexis Heng Boon Chin

May 22, 2026

Reform Singapore's Education System to Counter Fertility and Demographic Decline - A Policy Assessment White Paper

Singapore's competitive educational system is in urgent and dire need of radical reforms to overcome the nation's fertility and demographic crisis.

Alexis Heng Boon Chin

May 20, 2026

News and Opinion

Should Singapore Legislate Paid Fertility Leave for IVF Treatment? A Policy Brief and White Paper.

Legislated fertility leave is the decisive, common-sense step that Singapore must take to secure her demographic future.

Alexis Heng Boon Chin

May 06, 2026

Asian Bioethics Review

Behind the Paper

PGT-WGS (Preimplantation Genetic Testing with Whole Genome Sequencing) in Malaysia and Singapore

IVF Patients Beware! Profit-driven fertility clinics can readily exploit patients' ignorance and current sociocultural conditions to market the PGT-WGS platform that combines PGT-A, PGT-M, PGT-SR, and PGT-P for comprehensive IVF genetic testing, even though it cannot improve IVF success rates.

Alexis Heng Boon Chin

Mar 28, 2026

Health Care Analysis

Singapore’s low fertility rate cannot be rectified by new assisted reproductive technologies (ARTs) such as in vitro gametogenesis (IVG) and stem cell-based embryo models (SCBEMs)

Given that such new assisted reproductive technologies would be needed only by a tiny fraction of local patients facing extremely difficult infertility problems, these will not significantly improve Singapore’s ultra-low fertility rate. R&D for reproductive aims could be a waste of public resources.

Alexis Heng Boon Chin

Jun 12, 2025

Monash Bioethics Review

Behind the Paper

Confugenics - the East Asian Iteration of Consumer Eugenics Spells Demographic Disaster

A new terminology - “Confugenics” is thus proposed to describe the prospective intersection of such emerging human enhancement and reprogenetic technologies with the fixation on academic achievements and social status shaped by hyper-competitive social norms within East Asian societies.

Alexis Heng Boon Chin

Jun 03, 2025

Cookies

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website. You can decide for yourself which categories you want to deny or allow. Please note that based on your settings not all functionalities of the site are available.

Further information can be found in our privacy policy.